Cargando…

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing

Mutations in the serine/threonine kinase BRAF are found in more than 60% of melanomas. The most prevalent melanoma mutation is BRAF(V600E), which constitutively activates downstream MAPK signaling. Vemurafenib is a potent RAF kinase inhibitor with remarkable clinical activity in BRAF(V600E)-positive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salton, Maayan, Kasprzak, Wojciech K., Voss, Ty, Shapiro, Bruce A., Poulikakos, Poulikos I., Misteli, Tom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435825/ https://www.ncbi.nlm.nih.gov/pubmed/25971842 http://dx.doi.org/10.1038/ncomms8103

Ejemplares similares

Identification by high-throughput imaging of the histone methyltransferase EHMT2 as an epigenetic regulator of VEGFA alternative splicing
por: Salton, Maayan, et al.
Publicado: (2014)

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells
por: Bokharaie, Honey, et al.
Publicado: (2022)

Differential Recruitment of Pre-mRNA Splicing Factors to Alternatively Spliced Transcripts In Vivo
por: Mabon, Stephen A, et al.
Publicado: (2005)

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
por: Poulikakos, Poulikos I., et al.
Publicado: (2011)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Metastatic melanoma and vemurafenib: novel approaches
por: De Mello, Ramon Andrade
Publicado: (2012)

A STATement on Vemurafenib-Resistant Melanoma
por: Hartsough, Edward J., et al.
Publicado: (2013)

Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages
por: Effenberger, Kerstin A., et al.
Publicado: (2016)

Ectopic expression of Snord115 in choroid plexus interferes with editing but not splicing of 5-Ht2c receptor pre-mRNA in mice
por: Raabe, Carsten A., et al.
Publicado: (2019)

Pre-mRNA Splicing in the Nuclear Landscape
por: Carrocci, Tucker J., et al.
Publicado: (2020)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
por: Peng, Jianyu, et al.
Publicado: (2023)

Managing Side Effects of Vemurafenib Therapy for Advanced Melanoma
por: Hagen, Brenda, et al.
Publicado: (2014)

Insulin Reduces the Efficacy of Vemurafenib and Trametinib in Melanoma Cells
por: Osrodek, Marta, et al.
Publicado: (2020)

Sorafenib sensitizes melanoma cells to vemurafenib through ferroptosis
por: Tang, Fengjie, et al.
Publicado: (2020)

Matrin 3 Binds and Stabilizes mRNA
por: Salton, Maayan, et al.
Publicado: (2011)

RNA catalyzes nuclear pre-mRNA splicing
por: Fica, Sebastian M., et al.
Publicado: (2013)

Pre-mRNA splicing-associated diseases and therapies
por: Love, Sierra L., et al.
Publicado: (2023)

Prediction of alternative pre-mRNA splicing outcomes
por: Najjar, Rayan, et al.
Publicado: (2023)

Disruption of pre-mRNA splicing in vivo results in reorganization of splicing factors
Publicado: (1994)

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib
por: Castellani, Elisa, et al.
Publicado: (2012)

Vemurafenib resistance reprograms melanoma cells towards glutamine dependence
por: Hernandez-Davies, Jenny E, et al.
Publicado: (2015)

U1-independent pre-mRNA splicing contributes to the regulation of alternative splicing
por: Fukumura, Kazuhiro, et al.
Publicado: (2009)

A missense mutation in SNRPE linked to non-syndromal microcephaly interferes with U snRNP assembly and pre-mRNA splicing
por: Chen, Tao, et al.
Publicado: (2019)

MicroRNA-Biogenesis and Pre-mRNA Splicing Crosstalk
por: Shomron, Noam, et al.
Publicado: (2009)

Pre-mRNA Splicing Is a Determinant of Nucleosome Organization
por: Keren-Shaul, Hadas, et al.
Publicado: (2013)

Identification of Small Molecule Inhibitors of Pre-mRNA Splicing
por: Pawellek, Andrea, et al.
Publicado: (2014)

Quantification of pre-mRNA escape rate and synergy in splicing
por: Bonde, Marie Mi, et al.
Publicado: (2014)

Pre-mRNA splicing is a determinant of nucleosome organization
por: Keren-Shaul, Hadas, et al.
Publicado: (2013)

The Function of Pre-mRNA Alternative Splicing in Mammal Spermatogenesis
por: Song, Huibin, et al.
Publicado: (2020)

Alternative Splicing of Pre-mRNA in the Control of Immune Activity
por: Su, Zhongjing, et al.
Publicado: (2021)

The problem of selection bias in studies of pre-mRNA splicing
por: Dwyer, Zachary W., et al.
Publicado: (2023)

The role of alternative pre-mRNA splicing in cancer progression
por: Choi, Sunkyung, et al.
Publicado: (2023)

T cell therapy in combination with Vemurafenib in BRAF mutated metastatic melanoma patients
por: Borch, Troels Holz, et al.
Publicado: (2014)

Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma
por: Wolf, Sanne EJ, et al.
Publicado: (2013)

Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma
por: de Haan, Jorine, et al.
Publicado: (2018)

Dermoscopic assessment of skin toxicities in patients with melanoma during treatment with vemurafenib
por: Rajczykowski, Marcin, et al.
Publicado: (2018)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j9hodtk4djb3hcg04k8oeopa9g